NYSE:DGX - Quest Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $88.28 +0.18 (+0.20 %) (As of 12/12/2018 04:00 PM ET)Previous Close$88.10Today's Range$88.25 - $89.4952-Week Range$85.56 - $116.49Volume1.33 million shsAverage Volume1.04 million shsMarket Capitalization$11.91 billionP/E Ratio16.44Dividend Yield2.29%Beta0.9 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey. Receive DGX News and Ratings via Email Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Medical laboratories Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:DGX Previous Symbol CUSIP74834L10 Webwww.questdiagnostics.com Phone973-520-2700 Debt Debt-to-Equity Ratio0.63 Current Ratio1.15 Quick Ratio1.09 Price-To-Earnings Trailing P/E Ratio16.44 Forward P/E Ratio13.88 P/E Growth1.83 Sales & Book Value Annual Sales$7.71 billion Price / Sales1.56 Cash Flow$7.4498 per share Price / Cash Flow11.85 Book Value$36.35 per share Price / Book2.43 Profitability EPS (Most Recent Fiscal Year)$5.40 Net Income$772 million Net Margins11.30% Return on Equity15.71% Return on Assets7.56% Miscellaneous Employees45,000 Outstanding Shares136,070,000Market Cap$11.91 billion OptionableOptionable Quest Diagnostics (NYSE:DGX) Frequently Asked Questions What is Quest Diagnostics' stock symbol? Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics? Quest Diagnostics declared a quarterly dividend on Thursday, November 29th. Stockholders of record on Tuesday, January 15th will be given a dividend of $0.53 per share on Wednesday, January 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.40%. The ex-dividend date is Monday, January 14th. This is a boost from Quest Diagnostics's previous quarterly dividend of $0.50. View Quest Diagnostics' Dividend History. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics announced that its board has approved a share repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 7.8% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its stock is undervalued. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Inc (NYSE:DGX) announced its quarterly earnings data on Tuesday, October, 23rd. The medical research company reported $1.68 EPS for the quarter, meeting the consensus estimate of $1.68. The medical research company had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.95 billion. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The company's quarterly revenue was up 1.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 earnings per share. View Quest Diagnostics' Earnings History. When is Quest Diagnostics' next earnings date? Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Quest Diagnostics. What guidance has Quest Diagnostics issued on next quarter's earnings? Quest Diagnostics updated its FY18 earnings guidance on Thursday, November, 29th. The company provided EPS guidance of $6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.56. The company issued revenue guidance of ~$7.57 billion, compared to the consensus revenue estimate of $7.62 billion. What price target have analysts set for DGX? 17 brokers have issued 12 month price objectives for Quest Diagnostics' shares. Their forecasts range from $90.00 to $121.00. On average, they expect Quest Diagnostics' share price to reach $105.60 in the next year. This suggests a possible upside of 19.6% from the stock's current price. View Analyst Price Targets for Quest Diagnostics. What is the consensus analysts' recommendation for Quest Diagnostics? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quest Diagnostics. What are Wall Street analysts saying about Quest Diagnostics stock? Here are some recent quotes from research analysts about Quest Diagnostics stock: 1. Canaccord Genuity analysts commented, "We stick with our BUY rating, and lower our PT from $105 to $98, based on 14.3x our 2020 adj. EPS estimate." (11/30/2018) 2. According to Zacks Investment Research, "Over the past six months, Quest Diagnostics has been underperforming its industry. The company saw a sluggish performance in the last-reported quarter due to several factors including unfavorable weather impact on volume, unit price headwind and a critical change in revenue recognition accounting. Tough competitive landscape and reimbursement issues are other woes. However, we are optimistic about the company’s consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment. Quest Diagnostic’s latest acquisitions and collaborations with hospitals and integrated delivery networks (the latest buyout being MedXM) continue to act as major growth drivers. We are also upbeat about the company entering into strategic partnership agreement with UnitedHealthcare to join the latter's network for all plan participants from Jan 1, 2019 onwards." (5/25/2018) Has Quest Diagnostics been receiving favorable news coverage? Media headlines about DGX stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Quest Diagnostics earned a media sentiment score of 3.6 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Quest Diagnostics' key competitors? Some companies that are related to Quest Diagnostics include Laboratory Corp. of America (LH), ELEKTA AB/ADR (EKTAY), Guardant Health (GH), Genomic Health (GHDX), Natera (NTRA), CareDx (CDNA), InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN) and Fulgent Genetics (FLGT). Who are Quest Diagnostics' key executives? Quest Diagnostics' management team includes the folowing people: Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 61)Mr. Mark J. Guinan, Exec. VP & CFO (Age 56)Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 55)Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 55)Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 43) Who are Quest Diagnostics' major shareholders? Quest Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.66%), BlackRock Inc. (10.13%), Macquarie Group Ltd. (4.93%), American Century Companies Inc. (3.02%), Fiduciary Management Inc. WI (3.01%) and Victory Capital Management Inc. (1.97%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jenne K Britell, Jon R Cohen, Mark Guinan, Michael E Prevoznik, Robert A Klug and Stephen H Rusckowski. View Institutional Ownership Trends for Quest Diagnostics. Which institutional investors are selling Quest Diagnostics stock? DGX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Marshall Wace North America L.P., York Capital Management Global Advisors LLC, HealthCor Management L.P., Mitsubishi UFJ Trust & Banking Corp, AXA, Schroder Investment Management Group and Fiduciary Management Inc. WI. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Everett Cunningham, J E Davis, Jeffrey M Leiden, Jon R Cohen, Mark Guinan, Robert A Klug and Stephen H Rusckowski. View Insider Buying and Selling for Quest Diagnostics. Which institutional investors are buying Quest Diagnostics stock? DGX stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Marshall Wace LLP, Macquarie Group Ltd., Morgan Stanley, Vanguard Group Inc., Massachusetts Financial Services Co. MA, WINTON GROUP Ltd and Victory Capital Management Inc.. View Insider Buying and Selling for Quest Diagnostics. How do I buy shares of Quest Diagnostics? Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quest Diagnostics' stock price today? One share of DGX stock can currently be purchased for approximately $88.28. How big of a company is Quest Diagnostics? Quest Diagnostics has a market capitalization of $11.91 billion and generates $7.71 billion in revenue each year. The medical research company earns $772 million in net income (profit) each year or $5.40 on an earnings per share basis. Quest Diagnostics employs 45,000 workers across the globe. What is Quest Diagnostics' official website? The official website for Quest Diagnostics is http://www.questdiagnostics.com. How can I contact Quest Diagnostics? Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected] MarketBeat Community Rating for Quest Diagnostics (NYSE DGX)Community Ranking: 1.8 out of 5 ()Outperform Votes: 367 (Vote Outperform)Underperform Votes: 650 (Vote Underperform)Total Votes: 1,017MarketBeat's community ratings are surveys of what our community members think about Quest Diagnostics and other stocks. Vote "Outperform" if you believe DGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?